Results highlighted in two oral presentations at the American Society of Hematology Annual Meeting In a second oral presentation, results from a sub-group analysis of the primary study were ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYS: BMY) and Pfizer Inc. (NYS: PFE) today announced results of a post-hoc subanalysis from the Phase III ARISTOTLE trial.

The U.S. Food and Drug Administration has approved a Supplemental New Drug Application for Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) as a preventative measure against potential pulmonary ...

PRINCETON, N.J. & NEW YORK, Jun 27, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY -0.74% and Pfizer Inc. PFE -0.14% today announced that the Committee for Medicinal Products for Human Use ...

In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control ...

The novel oral anticoagulant apixaban has similar effects on stroke, systemic embolism and major bleeding in patients with atrial fibrillation (A-fib) whether they have been on previous warfarin ...

Please provide your email address to receive an email when new articles are posted on . Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or ...

Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure. Bleeding risk does not appear to increase when apixaban is given concomitantly with cardiac ...

But do these drugs really herald the end of warfarin, and how do doctors decide which of the three new agents to use? Two experts have quite different views of the situation. Dr Alexander Turpie ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--The Bristol-Myers Squibb-Pfizer Alliance today announced results from retrospective real-world data analyses reporting outcomes on the safety and ...